Results of ledipasvir/sofosbuvir treatment on with HCV genotype 1b infection / Монголын Анагаах Ухаан
Mongolian Medical Sciences
;
: 29-33, 2016.
Article
in English
| WPRIM
| ID: wpr-975612
ABSTRACT
IntroductionGenotype 1 infection has been historically difficult to treat, but multiple recent studies have showntreatment results greater than high in these genotype 1b patients using well-tolerated, all-oral regimensconsisting of new direct-acting antiviral agents.GoalPurpose of the study was to define the effects of ledipasvir/sofosbuvir treatment on patients with HCVgenotype 1b infection.Materials and MethodsIn this study we enrolled 2 treatment-naive and 66 treatment-experienced, totally 68 patients who tookledipasvir/sofosbuvir during the period from January 2016 to March 2016. We used randomly selectedand double-blinded method in our clinical research. The descriptive and non-parametrical statisticaltests were conducted using SPSS Statistics 20.0.ResultsThe SVR12 and SVR24 rates were greater than 95% and no differences were observed in treatmentnaiveversus treatment-experienced patients.ConclusionTheSVR12 rates were found in 98.6% while the SVR24 was in 97.1% of 68 patients. Only 2.9% of thetotal cases were appeared relapse of HCV infection. These findings indicated needs of further studieson long-term effects of ledipasvir/sofosbuvir.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Mongolian Medical Sciences
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS